Roche shareholders approved all Board of Directors proposals at the Annual General Meeting in Basel. Severin Schwan was re-elected as Chairman of the Board with a strong majority vote. The shareholders approved the 2024 financial statements, remuneration report, and sustainability report. A dividend increase to CHF 9.70 per share was approved, marking the 38th consecutive increase. All other Board members standing for election were also re-elected. Shareholders authorized the discharge of the Board of Directors and Corporate Executive Committee. The total bonuses for the Corporate Executive Committee for 2024 were approved. Maximum future remuneration for the Board of Directors and Corporate Executive Committee was also authorized. KPMG AG was appointed as statutory auditors for 2025. Roche highlighted its successful 2024, with increased demand for its products. The company emphasized its commitment to innovation and improving healthcare.